Your browser version may not work well with NCBI's Web applications. More information here...
1: Rev Epidemiol Sante Publique. 1990;38(3):187-99.Links

Economic evaluation of prophylactic treatment with Misoprostol in osteoarthritic patients treated with NSAIDs. The case of Belgium.

Carrin GJ, Torfs KE.

SESO, University of Antwerp (UFSIA), Belgique.

It is demonstrated in clinical studies that Misoprostol is effective in preventing gastric ulcers in osteoarthritic patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). The primary purpose of this article is to analyze the cost-effectiveness of Misoprostol. The methodology used is decision analysis. Clinical probability data for two patient groups (the Misoprostol and placebo group) were combined with data related to the costs of medical treatment and to the preventive use of Misoprostol. The basic conclusion is that the preventive treatment with Misoprostol entails net savings for society as a whole. However, the size of net savings is rather sensitive to changes in important parameters such as the presence of asymptomatic ulcers and the price of Misoprostol.

PMID: 2118670 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Misoprostol (Cytotec® )

    Misoprostol is used to prevent ulcers in people who take certain arthritis or pain medicines, including aspirin, that can cause ulcers. It protects the stomach lining and decreases stomach acid secretion.

  • Source: AHFS Consumer Medication Information